Abcellera Biologics Equity 2024

Abcellera Biologics Aktienanalyse

What does Abcellera Biologics do?

Abcellera Biologics Inc. is a leading biotechnology company specializing in the discovery of antibodies and the identification of therapies for serious diseases. The company was founded in Vancouver, Canada in 2012 and has since become a major player in the biotechnology field. It has formed numerous significant partnerships with large pharmaceutical companies in recent years and works closely with leading universities and research institutions worldwide. Abcellera Biologics Inc. follows a new, innovative business model that focuses on the discovery of antibodies through the application of cutting-edge technologies, data science, and machine learning. The company has developed a revolutionary technology platform called "Microfluidic Drop-based Technology" that is capable of discovering thousands of antibodies within just a few weeks. This technology allows for the rapid and efficient discovery of antibodies that can be used in the treatment of serious diseases. Abcellera Biologics Inc. is divided into several divisions that focus on antibody discovery, therapy development, collaborations with pharmaceutical companies, and services. Antibody discovery is carried out through years of research and development using state-of-the-art technologies and methods. Therapy development includes preclinical and clinical development of therapeutic products and conducting clinical trials. Abcellera Biologics Inc. works closely with leading pharmaceutical companies in the industry to develop new therapies and discover antibodies. The company has already formed numerous partnerships with major pharmaceutical companies such as Pfizer, Sanofi, GlaxoSmithKline, AbbVie, and Biogen. Another important focus of Abcellera Biologics Inc. is providing services in the field of antibody development. The company has extensive expertise in antibody discovery and therefore offers services to other companies. This allows other companies to benefit from Abcellera Biologics Inc.'s unique technology platform and top-notch capabilities. Abcellera Biologics Inc.'s product portfolio includes various antibody therapies targeting the treatment of specific diseases. One of the company's most promising products is the "LY-CoV555" antibody therapy used for COVID-19. This therapy was developed in collaboration with Eli Lilly and is currently being tested in clinical trials. Overall, Abcellera Biologics Inc. has become a leading company in the biotechnology industry. Its focus on antibody discovery through state-of-the-art technologies and data-driven methods, as well as successful collaborations with major pharmaceutical companies, makes it an important player in the industry. Abcellera Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Abcellera Biologics's Equity

Abcellera Biologics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Abcellera Biologics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Abcellera Biologics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Abcellera Biologics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Abcellera Biologics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Abcellera Biologics stock

What is the equity of Abcellera Biologics this year?

Abcellera Biologics has equity of 1.15 B USD this year.

What was the equity of Abcellera Biologics compared to the previous year?

The equity of Abcellera Biologics has increased/decreased by -6.57% decreased compared to the previous year.

What impact does a high equity have on investors of Abcellera Biologics?

A high equity is advantageous for investors of Abcellera Biologics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Abcellera Biologics?

A low equity can be a risk for investors of Abcellera Biologics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Abcellera Biologics affect the company?

An increase in equity of Abcellera Biologics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Abcellera Biologics affect the company?

A reduction in equity of Abcellera Biologics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Abcellera Biologics?

Some factors that can affect the equity of Abcellera Biologics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Abcellera Biologics so important for investors?

The equity of Abcellera Biologics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Abcellera Biologics take to change the equity?

To change equity, Abcellera Biologics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Abcellera Biologics pay?

Over the past 12 months, Abcellera Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abcellera Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of Abcellera Biologics?

The current dividend yield of Abcellera Biologics is .

When does Abcellera Biologics pay dividends?

Abcellera Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abcellera Biologics?

Abcellera Biologics paid dividends every year for the past 0 years.

What is the dividend of Abcellera Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abcellera Biologics located?

Abcellera Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abcellera Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abcellera Biologics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Abcellera Biologics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Abcellera Biologics in the year 2023?

In the year 2023, Abcellera Biologics distributed 0 USD as dividends.

In which currency does Abcellera Biologics pay out the dividend?

The dividends of Abcellera Biologics are distributed in USD.